The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment | Zendy

Simon P. Duffy | Zendy; Truxton L. Jackson | Zendy; Mark Lansdown | Zendy; Kamaira Philips | Zendy; Michael Wells | Zendy; S. Pollard | Zendy; Glen Clack | Zendy; Michel Coibion | Zendy; Antonio Bianco | Zendy

Open Access

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment

Author(s) -

Simon P. Duffy,

Truxton L. Jackson,

Mark Lansdown,

Kamaira Philips,

Michael Wells,

S. Pollard,

Glen Clack,

Michel Coibion,

Antonio Bianco

Publication year - 2005

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dei322

Subject(s) - anastrozole , tamoxifen , medicine , aromatase inhibitor , endometrial cancer , breast cancer , tolerability , oncology , gynecology , odds ratio , urology , cancer , adverse effect

Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years. Anastrozole, a third-generation aromatase inhibitor, with superior efficacy to tamoxifen, may also offer tolerability benefits in terms of effects on the endometrium.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research